Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
467results about How to "Delay progress" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Morphinan-derivatives for treating diabetes and related disorders
ActiveUS20150087669A1Risk of developingDelay progressBiocideMetabolism disorderDiseaseNR1 NMDA receptor
The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I)whereinR1 is selected from —OH, —CO2H, —R0, —OR0, —OC(═O)R0, —OC(═O)OR0 or —OC(═O)NHR0; and R2 is selected from —H, —R0, —C(═O)R0, —C(═O)OR0, —C(═O)NHR0 or —C(═NH)—NH—C(═NH)—NH2; wherein R0 is in each case independently selected from —C1-C6-alkyl, -aryl, -heteroaryl, —C1-C6-alkyl-aryl or —C1-C6-alkyl-heteroaryl, in each case independently unsubstituted or substituted;or its physiologically acceptable salt and / or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, and / or diabetic nephropathy.
Owner:DEUTE DIABETES FORSCHUNGSGES
Methods and devices for renal nerve blocking
InactiveUS20050192638A1Shorten the progressResolution of overloadPharmaceutical delivery mechanismImplantable neurostimulatorsRenal nerveImplanted device
A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.
Owner:MEDTRONIC ARDIAN LUXEMBOURG SARL
Method of radiation delivery to the eye
InactiveUS6875165B2Optimal balance of powerOptimal balance of penetrationDiagnosticsSurgeryOcular operationRadical radiotherapy
A surgical device for localized delivery of beta radiation in surgical procedures, particularly ophthalmic procedures. Preferred surgical devices include a cannula with a beta radiotherapy emitting material at the distal end of the cannula. The surgical device is particularly suitable for use in the treatment of treat Age Related Macular Degeneration (AMD).
Owner:RETINALABS COM
Human Anti-Tau Antibodies
Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:UNIV ZURICH +1
Treatment of fatty liver
InactiveUS20070265340A1Shorten the progressIncreased riskBiocideDigestive systemFatty liverBeta oxidation
Methods and compositions comprising peroxisomal and / or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated with an increased risk of fatty liver development and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure, may be administered in combination with peroxisomal and / or mitochondrial beta oxidation stimulating agents. A combination regimen involving such agents, as simultaneous or concomitant therapy, or as a fixed dosage form, is also provided.
Owner:RELIANT PHARMACEUTICALS INC
Selective androgen receptor modulators and methods of use thereof
InactiveUS20060241180A1Shorten the progressPrevent relapseBiocideGroup 4/14 element organic compoundsDiseaseSelective androgen receptor modulator
This invention provides a class of androgen receptor targeting agents (ARTA). The compounds are selective androgen receptor modulators (SARM) useful for, inter-alia, suppressing spermatogenesis, treating a subject having a hormone related condition, treating a subject suffering from prostate cancer, delaying the progression of prostate cancer, preventing the recurrence of prostate cancer, and treating the recurrence of prostate cancer.
Owner:UNIV OF TENNESSEE RES FOUND
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20090220489A1Reduce developmentDelay progressOrganic active ingredientsNervous disorderVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Methods and compositions for slowing aging
InactiveUS20070179174A1Anti agingImprove the quality of lifeBiocideAnimal repellantsQuality of lifePathology diagnosis
The present invention provides a pharmacological agent based on derivatives of hydrogenated pyrido (4,3-b) indoles and uses thereof. Specifically, the invention provides a geroprotector in the series of hydrogenated pyrido (4,3-b) indoles (several derivatives), which can be used for slowing aging, prolonging lifespan of an individual or cells in an individual, and / or improving quality of life of an individual developing or having a risk of developing age-associated manifestations and / or pathologies.
Owner:MEDIVATION TECH INC
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS8007794B2Reduce developmentDelay progressOrganic active ingredientsNervous disorderVasomotor symptomCalcitonin gene-related peptide
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Human Anti-tau antibodies
InactiveUS20130295021A1Reduce riskSlow onsetBacteriaPeptide/protein ingredientsTargeted immunotherapySpecific antibody
Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1
Chemoprotective methods and compositions
InactiveUS20080193498A1Low level of severe peripheral neuropathyReduce and prevent and mitigate and delayBiocideAntinoxious agentsMedicineChemoprotection
Compositions and methods for reducing, preventing, mitigating, and / or delaying the onset of, attenuating the severity of, and / or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents. In addition compositions and methods for mitigating or preventing a novel form of chemotherapy-induced peripheral neuropathy are disclosed and claimed.
Owner:BIONUMERIK PHARMA INC
Ophthalmic treatment apparatus
InactiveUS20050177019A1Easy to useIncrease exposureMedical devicesMedical applicatorsGreek letter betaOcular operation
Owner:RETINALABS COM
Drug Screen and Treatment Method
InactiveUS20080221074A1Treat and ameliorate metabolic disorderTreat or ameliorate a metabolic disorderOrganic active ingredientsMicrobiological testing/measurementAcute hyperglycaemiaMedicine
The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one.
Owner:NEURMEDIX +2
Human anti-tau antibodies
ActiveUS8940272B2Reduce riskSlow onsetBacteriaLibrary screeningTargeted immunotherapySpecific antibody
Owner:UNIV ZURICH +1
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ActiveUS20170182123A1Improves bile acid homeostasisReduce doseAntibody mimetics/scaffoldsSulfonylurea active ingredientsDiseaseFGF19
Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
Owner:NGM BIOPHARMLS
Ophthalmic lens with progressive addition of power and prism
ActiveUS7216977B2Avoid problemsAvoid disturbing balanceSpectales/gogglesOptical partsPrismNear vision
The lens presents horizontal prismatic refractive power that varies progressively along the main progression meridian (MM′) with the addition of horizontal prismatic power being greater than 2 prismatic diopters in absolute value, this addition of horizontal prismatic power being defined by the difference between the horizontal prismatic refractive power at the reference point (L) of the far vision zone and the horizontal prismatic refractive power at the projection point (P′) of the reference point (P) of the near vision zone (VP) on the vertical line passing through the reference point (L) of the far vision zone.
Owner:ESSILOR INT CIE GEN DOPTIQUE
Medical use of a dpp-4 inhibitor
ActiveUS20150246045A1Delay progressDelaying onsetBiocideMetabolism disorderHeart failure with preserved ejection fractionCvd risk
The present invention relates to the use of a certain DPP-4 inhibitor for use in a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF).
Owner:BOEHRINGER INGELHEIM INT GMBH
Treatment of Fatty Liver
InactiveUS20090182022A1Shorten the progressAvoid developmentBiocideDigestive systemBeta oxidationActive agent
Methods and compositions comprising peroxisomal and / or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated with an increased risk of fatty liver development and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure, may be administered in combination with peroxisomal and / or mitochondrial beta oxidation stimulating agents. A combination regimen involving such agents, as simultaneous or concomitant therapy, or as a fixed dosage form, is also provided.
Owner:RELIANT PHARMACEUTICALS INC
Amine Cationic Lipids and Uses Thereof
ActiveUS20140371293A1Diminishment of extentAvoid spreadingOrganic active ingredientsBiocideLipid formationIn vivo
The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).
Owner:DICERNA PHARM INC
Drug Screening and Treatment Methods
InactiveUS20080146532A1Treat and ameliorate metabolic disorderTreat or ameliorate a metabolic disorderOrganic active ingredientsMetabolism disorderDiseaseTriol
The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β, 7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one.
Owner:BIOVIE INC
Targeted binding agents directed to dll4 and uses thereof 524
InactiveUS20100196385A1Improve abilitiesEasy to fixAntibacterial agentsSenses disorderDiseaseMonoclonal antibody
The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and / or overproduction of DLL4 and as diagnostics.
Owner:MEDIMMUNE LLC
Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
InactiveUS20080161203A1Cure and slow down liver fibrosis progressionSlow curingPeptide librariesHydrolasesCFHR5Biology
In the present invention, the markers identified for liver fibrosis and cirrhosis and the microarray panel thereof comprise at least one of the following proteins / genes:8 up-regulated genes such asANXA2; COL1A2; COL3A1; GSN; LDHB; LUM; PDGFRA and TIMP1.13 down-regulated genes such asALB; ANPEP; APOF; AZGP1; BHMT C8A; CFHR4; CFHR5; COL18A1; FTCD; GYS2; ITIH1, and THRAP1.9 therapeutic targets such as PDGFRA; S100A4; COL3A1; CCL19; DCN; DPT; APP; TNF; and INFG.The present invention is capable of screening markers for the early warning of the occurrence for severe fibrosis or cirrhosis and potentially targets for drug design.
Owner:VITA GENOMICS
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20150266948A1Reduce developmentDelay progressNervous disorderImmunoglobulins against animals/humansVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20150322142A1Reduce developmentDelay progressNervous disorderImmunoglobulins against animals/humansVasomotor symptomCluster headache
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
ActiveUS20120009192A1Reduce developmentDelay progressOrganic active ingredientsFungiVasomotor symptomCalcitonin
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Anti-tirc7 antibodies in therapy of inflammatiory diseases
ActiveUS20060251646A1Opportunity to healAmelioration of these conditionsOrganic active ingredientsFungiAnti-inflammatoryAntibody
A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises particular therapeutic and preventive treatment regimens for the administration of a T-cell immune response cDNA 7 (TIRC7) antagonist, preferably an anti-TIRC7 antibody. Particularly useful monoclonal, in particular chimeric anti-TIRC7 antibodies are described. Furthermore, a combination therapy for the treatment of an inflammatory disease, particularly rheumatoid arthritis, is provided involving the use of TIRC7 antagonist, such as anti-TIRC7 antibody in conjunction with an anti-inflammatory drug such as TNF-α antagonist
Owner:GENPAT77 PHARMACOGENETICS
Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
InactiveUS20120282176A1Effectively crossDiminishment of any direct or indirect pathological consequencesAntibacterial agentsNervous disorderBinding siteVariable domain
Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
Owner:ROCHE GLYCART AG
Composition to retard the onset of symptoms of alzheimer's disease
A composition and a method for using the composition to delay the onset of the symptoms of Alzheimer's disease in humans, comprising curcumin, piperine, oleic acid, oleanolic acid, ursolic acid, galantamine, and huperzine A, among other compounds. Curcumin is an antioxidant, while galantamine and huperzine A inhibit the activity of acetylcholinesterase in the brain. Piperine and oleic acid increase the bioavailability and gastrointestinal absorption of curcumin, galantamine, huperzine A, and other nutrients.
Owner:CONSEAL INT
Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias
ActiveUS20160256429A1Reduce Toxicity RiskImprove the situationOrganic active ingredientsMetabolism disorderDyslipidemiaSterol
The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and / or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and / or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and / or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and / or treating a pathological condition selected from metabolic syndrome and / or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.
Owner:CENT NAT DE LA RECHERCHE SCI +2
Method and apparatus for treatment of amyotrophic lateral sclerosis patients
InactiveUS20070282388A1Improving and ameliorating symptomDelay progressElectrotherapyMagnetotherapy using coils/electromagnetsSquare waveformMedicine
A method for treating patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. In accordance with the method of treatment, transcranial AC pulsed electromagnetic fields (EMFs) in substantially square waveforms in particular frequency and amplitude ranges and picotesla quantities are applied to the patient's brain. EMFs are applied via a transducer array containing a plurality of flexible circular coils in an arrangement placed over the scalp of an ALS patient. The treatment method ameliorates symptoms associated with the disease state and slows the progression of the disease.
Owner:SANDYK REUVEN
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com